Who are Randomisation to omalizumab's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/randomisation-to-omalizumab.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-15 · How we verify

Randomisation to omalizumab — Competitive Intelligence Brief

Randomisation to omalizumab (Randomisation to omalizumab) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: IgE antagonist monoclonal antibody. Area: Immunology / Allergy.

marketed IgE antagonist monoclonal antibody Immunoglobulin E (IgE) Immunology / Allergy Small molecule Live · refreshed every 30 min

Target snapshot

Randomisation to omalizumab (Randomisation to omalizumab) — Cliniques universitaires Saint-Luc- Université Catholique de Louvain. Omalizumab is a monoclonal antibody that binds to circulating immunoglobulin E (IgE), preventing its interaction with high-affinity IgE receptors on mast cells and basophils.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Randomisation to omalizumab TARGET	Randomisation to omalizumab	Cliniques universitaires Saint-Luc- Université Catholique de Louvain	marketed	IgE antagonist monoclonal antibody	Immunoglobulin E (IgE)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (IgE antagonist monoclonal antibody class)

Cliniques universitaires Saint-Luc- Université Catholique de Louvain · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Randomisation to omalizumab — Competitive Intelligence Brief. https://druglandscape.com/ci/randomisation-to-omalizumab. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab